TGFB1 and neoplasm: These data suggest that PD-L1/PD-1 checkpoint and TGFβ signaling exercise independent, yet cooperative mechanisms of immune tolerance, thereby supporting a therapeutic rationale for simultaneously counteracting both axes in the tumor immune microenvironment.